(Date:7/25/2008)... - 180-Days of Marketing Exclusivity Beg...all/ -- Watson,Pharmaceuticals, Inc. (NYSE: WPI )...unced today that its subsidiary has commenced comm...Capsules USP product in the 40mg,strength from its...tion,with the launch, Watson has 180 days of marke...
(Date:7/25/2008)...CHAUMBURG, Ill., July 25 /PRNewswire/ -- Sagent Ph...armaceutical company, today announced that it,has ...I antiarrhythmic,indicated for the treatment and p...rillation and hemodynamically unstable ventricular...egular heart beat.,Sagent,s amiodarone HCl injecti...
(Date:7/25/2008)...ARLSBAD, Calif., July 25 /PRNewswire/ -- AutoGenom...stration statement on Form S-1 with the,Securities...initial public,offering of shares of its common st...fered, all of which are expected to be offered by,...fering, have not yet been,determined., J.P. Morga...
(Date:7/25/2008)... New program delivers immediat...ml [24-hour telephone access to language interpre...eking multilingual solutions. , ...-- LLE® http://www.lle-inc.com/index.html [...provider of interpretation, translation, and langu...
Breaking Medicine News(10 mins):Health News:Watson Launches Omeprazole Delayed-Release Capsules, 40MG 2Health News:Sagent Pharmaceuticals Launches Amiodarone HCl Injection, USP 2Health News:Sagent Pharmaceuticals Launches Amiodarone HCl Injection, USP 3Health News:AutoGenomics, Inc. Files Registration Statement for Initial Public Offering 2Health News:LLE Launches Over-the-Phone Interpretation OPI Easy Switch Program 2Health News:LLE Launches Over-the-Phone Interpretation OPI Easy Switch Program 3...ptoms of Money sickness syndrome (MSS) due to impr...d by the insurance giant AXA found that Britons ha...ems //due to the feeling that they are not in cont...e Britons have experienced symptoms such as palpit...
...roversy prevails over a case lodged by a wife agai... accused of infecting her with the deadly virus. A.../ status before the marriage. Furthermore, he is s...f HIV infection over a period of 6 months. The wo...
...merican scientist of Indian origin has been declar... a new system which makes use of data for improvin...o is the Senior Director of Engineering Research D...s' Computer-aided Diagnosis and Therapy Group. R...
...has stopped the removing of life support to an 11-...improving after four months in a coma. The coma wa...ved from her stepfather and adoptive mother. The g... months, and her coma was declared irreversible by...
Other Medicine News:(Date:7/22/2008)...tes Feasibility and Efficacy of Treating Patients ..., SAN FRANCISCO, and YONGIN-SI, South Korea, July... CA and Ottawa, Ontario), and its South,Korean par... findings from,a Phase I clinical trial of its fir...the product was well-tolerated and resulted in cle...
(Date:7/22/2008)...lan Will Stress the Importance to Patients of Pass...l Pathway, RICHMOND, Va., July 22 /PRNewswire-Fir...er of follow-on biologics and biopharmaceuticals, ... Insmed, will present at a,Congressional briefing ...ant need for establishing an approval pathway for ...
(Date:7/22/2008)... Validated by Columbia University Medical Center B...croRNA Technology, The Test Differentiates Squam...(NSCLC), Classifying Squamous-Cell Carcinoma of th...pecificity of 90 Percent,This is the First CLIA Ap... as Biomarkers for Accurate Diagnosis of ...
(Date:7/22/2008)...s an Individual,s Genetic Risk Based on Clinical D... Educational Materials, WALTHAM, Mass., July 22 /.... (Amex: ILI ), today announced the launch of an ...e for the company,s Heart Health Genetic Test.,The...ensona(R) Heart Health,Genetic Test by Quixtar/Amw...
Breaking Medicine Technology:Jennerex Publishes Clinical Trial Data With Lead Product JX-594 Demonstrating Efficacy Against Liver Cancer and Associated Hepatitis B Virus 2Jennerex Publishes Clinical Trial Data With Lead Product JX-594 Demonstrating Efficacy Against Liver Cancer and Associated Hepatitis B Virus 3Jennerex Publishes Clinical Trial Data With Lead Product JX-594 Demonstrating Efficacy Against Liver Cancer and Associated Hepatitis B Virus 4Insmed CEO to Present at Congressional Briefing on Follow-On Biologics 2Insmed CEO to Present at Congressional Briefing on Follow-On Biologics 3First Cancer Diagnostic Test Based on Rosetta Genomics' Proprietary MicroRNA Technology Receives Regulatory Approval 2First Cancer Diagnostic Test Based on Rosetta Genomics' Proprietary MicroRNA Technology Receives Regulatory Approval 3First Cancer Diagnostic Test Based on Rosetta Genomics' Proprietary MicroRNA Technology Receives Regulatory Approval 4First Cancer Diagnostic Test Based on Rosetta Genomics' Proprietary MicroRNA Technology Receives Regulatory Approval 5Interleukin Genetics Launches Enhanced Heart Health Genetic Test Report Format 2Interleukin Genetics Launches Enhanced Heart Health Genetic Test Report Format 3APC papers in global theme issue on poverty 4283 1Can the Web Transform the U S Healthcare System 3F 4281 1Can the Web Transform the U S Healthcare System 3F 4281 2Can the Web Transform the U S Healthcare System 3F 4281 3DoD and VA to Reduce Healthcare Supply Chain Costs 4279 1DoD and VA to Reduce Healthcare Supply Chain Costs 4279 2DoD and VA to Reduce Healthcare Supply Chain Costs 4279 3DoD and VA to Reduce Healthcare Supply Chain Costs 4279 4New Round of Lupus Research Institute Awards Brings Promise of More Breakthroughs 4277 1New Round of Lupus Research Institute Awards Brings Promise of More Breakthroughs 4277 2New Round of Lupus Research Institute Awards Brings Promise of More Breakthroughs 4277 3New Round of Lupus Research Institute Awards Brings Promise of More Breakthroughs 4277 4.../PRNewswire/ -- A three-year,follow-up subset an...al trial at EuroPCR 2007 showed that the CYPHER(R)...mparable to coronary,artery bypass grafting (CAB...re metal stents (BMS) in diabetic patients with bl...e CYPHER(R) Stent results in the diabetic populati...
...--May 22, 2007 - The National,Comprehensive Cancer...ical Practice Guidelines in Oncology(TM) -- Esopha...s are updated continuously by,panels of world-reno... as the standard of care in oncology in the United...ctice settings., In response to favorable Phase II...
Other Medicine Technology:Cypher Sirolimus-Eluting Coronary Stent Had Similar Results to,Bypass Surgery and Better Outcomes Than Bare Metal Stents in,Subgroup Analysis of Diabetic Patients With Multivessel Coronary,Disease 2Cypher Sirolimus-Eluting Coronary Stent Had Similar Results to,Bypass Surgery and Better Outcomes Than Bare Metal Stents in,Subgroup Analysis of Diabetic Patients With Multivessel Coronary,Disease 3Cypher Sirolimus-Eluting Coronary Stent Had Similar Results to,Bypass Surgery and Better Outcomes Than Bare Metal Stents in,Subgroup Analysis of Diabetic Patients With Multivessel Coronary,Disease 4NCCN Updates Esophageal and Gastric Cancer Guidelines 2NCCN Updates Esophageal and Gastric Cancer Guidelines 3...leep System is an easy-to-use, workflow-based syst...lts. Inspirex consists of the SleepWorks software...ugged and durable systems can be used for a comple...s - including full EEG recording - and have superi...
...ieval System is made up of three integral componen...ter and the Merci Balloon Guide Catheter. The syst... Once the location of the clot has been identified...er is inserted through a small incision in the fem...
... level of care you can provide to your patients, D...ng innovative products, standardization and reimbu...Davol® pulsed lavage systems deliver the perfo...otic tissue, bacteria, and foreign material. Each ...
The Simpulse Solo Pulsed Lavage System requires minimal set up and has a Wide range of tips available for every orthopaedic procedure. It uses a separate suction lumen to reduce clogging and n ergono
Medicine Products: